Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder. NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate (NMDA NR2B) […]
Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgenetic Alopecia (AGA). This Proof-of-Concept clinical trial in the AGA program included daily dosing for four months in a study entitled, “A Randomized, Double-Blind, Vehicle-Controlled, […]
K36 Therapeutics, Inc. (“K36”), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams. Dr. Winograd joins K36 with a wealth of experience and a remarkable track record of bringing innovative medicines […]
VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the early detection of bladder cancer, today announced that William T. Lowrance, MD, MPH, MBA will serve as the company’s Chief Medical Officer. Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a […]
Inner Haven Wellness announces the appointment of Margherita Mascolo, MD, CEDS-S as Chief Medical Officer. With a history of dedicated healthcare leadership and clinical expertise, Dr. Mascolo will play a pivotal role in ensuring the organization delivers industry-leading treatment and achieves excellent patient outcomes. Dr. Mascolo has built eating disorder treatment programs at every level […]
